ArTec Inc., of Reno, Nevada, Announces Its Readiness to Review PRECLINICAL APPLICATION with US FDA - Tubercin-Anti-Cancer Immunostimulant.

RENO, Nev. -- ArTec, Inc., www.artec-inc.net (Pink Sheets:ATKJ) The Pharmaceutical Company's Board of Directors has given a directive to management to prepare for PRECLINICAL US FDA APPLICATION. Specifically, a committee was designated the responsibility to prepare for reviewing PRIVATE MEDICAL REGULATORY CONSULTANTS to lead ArTec, Inc.'s efforts. In the PRECLINICAL phase: in vitro and in vivo, non-human studies are considered. In the same vein, ArTec, Inc., will prepare to review possible PRECLINICAL COLLABORATORS. At the PRECLINICAL stage, determination will be made about the basis for applying under the investigational new drug application (IND) to the FDA.

The stages for PHASE 1, PHASE 2 and PHASE 3 consist of human studies. At the beginning, ArTec, Inc. plans to include resources involving CLINICAL COLLABERATORS, ALLIANCES and possible GRANTS-SPECIAL RESEARCH PROJECTS to assist Tubercin in completing the FDA approval process. No doubt the FAST TRACK status will also be considered in light of the origin of Tubercin at a highly accredited University facility with clinical treatments and evaluations occurring on site.

Tubercin is "carbohydrate complex, which is a mixture of low molecular-weight polysaccharides of an arabinomannan structure extract from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects." For further information, the US Patent and Trademark Office's Official web site is retrievable at our web site: www.artec-inc.net.

Forward-looking statements in this press release, the company cautions the investors, involve risks and uncertainties pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. In addition, the company cautions investors that it undertakes no obligations or responsibilities to publicly update these forward-looking statements to reflect Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.